Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.

Cassava Sciences' RETHINK-ALZ trial is nearing data release. See why SAVA stock could see volatility depending on trial ...

Cassava Sciences ( (SAVA) ) has released its Q3 earnings. Here is a breakdown of the information Cassava Sciences presented to its investors.

Today, Benzinga's options scanner spotted 8 options trades for Cassava Sciences. This isn't normal. The overall sentiment of ...

Top-line Data for RETHINK-ALZ 52-week Phase 3 trial Expected Before the End of 2024 $149.0 Million in Cash and Cash ...

The stock has been up 30% since Tuesday, and its market cap has now reached more than $1 trillion. SAVA: Cassava Sciences is ...

Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...

Detailed price information for Cassava Sciences Inc (SAVA-Q) from The Globe and Mail including charting and trades.

More U.S. investors are launching companies stateside that license technology from China, even as Congress moves to crack down on some Chinese companies through the BIOSECURE Act. Read more.

Investors with a lot of money to spend have taken a bearish stance on Cassava Sciences (NASDAQ:SAVA). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Bearish flow noted in Cassava Sciences (SAVA) with 2,978 puts trading, or 1.3x expected. Most active are Nov-24 27 puts and Dec-24 10 puts, ...